Inovio Pharmaceuticals, Inc. (NASDAQ:INO) was downgraded by equities research analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a report issued on Friday.

Other equities research analysts also recently issued research reports about the stock. Maxim Group reissued a “buy” rating and set a $12.00 price target on shares of Inovio Pharmaceuticals in a research report on Tuesday, September 12th. HC Wainwright set a $13.00 price target on shares of Inovio Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, July 27th. Zacks Investment Research raised shares of Inovio Pharmaceuticals from a “hold” rating to a “buy” rating and set a $8.75 price target for the company in a research report on Tuesday, July 11th. Finally, Citigroup Inc. began coverage on shares of Inovio Pharmaceuticals in a research report on Wednesday, September 6th. They set a “buy” rating and a $10.00 price target for the company. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and eight have issued a buy rating to the company’s stock. Inovio Pharmaceuticals presently has an average rating of “Hold” and an average price target of $19.16.

Inovio Pharmaceuticals (NASDAQ INO) traded up 3.74% during trading on Friday, hitting $5.83. The stock had a trading volume of 1,006,252 shares. The stock’s 50-day moving average price is $6.19 and its 200-day moving average price is $6.62. The company’s market capitalization is $526.02 million. Inovio Pharmaceuticals has a 1-year low of $5.28 and a 1-year high of $9.86.

Inovio Pharmaceuticals (NASDAQ:INO) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.21) by $0.08. The company had revenue of $20.41 million during the quarter, compared to the consensus estimate of $16.29 million. Inovio Pharmaceuticals had a negative net margin of 153.46% and a negative return on equity of 63.67%. The firm’s quarterly revenue was up 229.2% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.26) earnings per share. Analysts expect that Inovio Pharmaceuticals will post ($0.95) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This piece of content was published by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another site, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/10/29/inovio-pharmaceuticals-inc-ino-downgraded-by-bidaskclub-to-strong-sell.html.

Large investors have recently bought and sold shares of the business. Wasatch Advisors Inc. grew its position in Inovio Pharmaceuticals by 43.6% in the 2nd quarter. Wasatch Advisors Inc. now owns 2,610,818 shares of the biopharmaceutical company’s stock worth $20,469,000 after purchasing an additional 793,306 shares during the period. Wells Fargo & Company MN grew its position in Inovio Pharmaceuticals by 28.9% in the 1st quarter. Wells Fargo & Company MN now owns 124,565 shares of the biopharmaceutical company’s stock worth $825,000 after purchasing an additional 27,898 shares during the period. Bank of New York Mellon Corp grew its position in Inovio Pharmaceuticals by 3.6% in the 1st quarter. Bank of New York Mellon Corp now owns 342,348 shares of the biopharmaceutical company’s stock worth $2,266,000 after purchasing an additional 11,765 shares during the period. ARK Investment Management LLC grew its position in Inovio Pharmaceuticals by 79.2% in the 2nd quarter. ARK Investment Management LLC now owns 65,901 shares of the biopharmaceutical company’s stock worth $517,000 after purchasing an additional 29,128 shares during the period. Finally, Vanguard Group Inc. grew its position in Inovio Pharmaceuticals by 7.9% in the 1st quarter. Vanguard Group Inc. now owns 3,098,055 shares of the biopharmaceutical company’s stock worth $20,510,000 after purchasing an additional 226,861 shares during the period. 25.05% of the stock is owned by institutional investors and hedge funds.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Analyst Recommendations for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.